Frenova, Nephronomics, and GENEWIZ collaborate for precision kidney disease care and diagnostics.

Frenova and Nephronomics have initiated a collaboration with GENEWIZ by Azenta Life Sciences to analyze genomic data from Frenova's My Reason® registry. The partnership aims to advance precision kidney disease care, novel therapies, and diagnostics. By leveraging cutting-edge technologies, the collaboration will provide vital insights into kidney, cardiovascular, and metabolic diseases.

Fresenius Medical Care has announced a strategic collaboration between its third-party clinical research organization, Frenova, and Nephronomics, a renal precision medicine company co-founded by Fresenius Medical Care. The collaboration involves GENEWIZ by Azenta Life Sciences, with the aim of advancing genomic analysis efforts for Frenova's transformative My Reason® genomics research program [1].

The partnership leverages cutting-edge technologies to better understand kidney, cardiovascular, and metabolic diseases, driving advancements in precision medicine for patients worldwide. Frenova's My Reason® genomics research program is a kidney-focused data registry composed of genomic and clinical patient data designed to uncover insights into the genetic mechanisms underlying kidney disease [2].

Frenova's registry, which includes over 35,000 participants with a goal of reaching 50,000 within the next two years, will be analyzed by GENEWIZ using sophisticated genomic sequencing and analysis. GENEWIZ will provide large-scale genomic data from biospecimens collected through Frenova's extensive nephrology research network, as well as long-term storage of samples through its global biorepository network [3].

Nephronomics holds exclusive commercial rights to the My Reason® dataset, which anchors the Nephronomics Atlas, a resource of deep clinical and genomic cardio-kidney-metabolic (CKM) disease data. The collaboration will enable Nephronomics to unlock new insights that could transform patient care by identifying novel disease subtypes, protective genetic variants, and therapeutic targets [2].

This collaboration marks a significant step forward in the journey to build the most comprehensive genotype-phenotype database for patients with cardiovascular, kidney, and metabolic diseases. By harnessing advanced genetic and molecular insights, the partnership aims to transform kidney care, making it more personalized, precise, and responsive to each patient's distinct needs [1].

References:
[1] https://freseniusmedicalcare.com/en/media/newsroom/third-party-clinical-research-organization-frenova-announces-strategic-collaboration-advancing-genomics-driven-precision-kidney-disease-care/
[2] https://www.marketscreener.com/news/fresenius-medical-care-s-third-party-clinical-research-organization-frenova-announces-strategic-coll-ce7c5fddda8cf725
[3] https://www.stocktitan.net/news/FMS/fresenius-medical-care-s-third-party-clinical-research-organization-iwenxug1o0u2.html